Biotechnology major Biocon and Mylan NV on Thursday launched biosimilar Ogivri, which is used for treatment of certain breast and stomach cancers in Australia. It is a biosimilar of Hoffmann-La Roches Herceptin.
Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme (PBS), the companies said in a joint statement.
